RenovoRx Q3 2026 Results: Net Loss of $3.65M, Loss Widens
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on its TAMP therapy platform and Phase III TIGeR-PaC trial. As of October 30, 2026, the company reported 48,250,592 shares of common stock outstanding and maintains its status as a smaller reporting and emerging growth company. The filing includes condensed financial statements for the period ending September 30, 2026, highlighting ongoing commercialization efforts for the RenovoCath device.
- Key figure
- Net loss $3.65M